HomeCompareGPOVY vs ABBV

GPOVY vs ABBV: Dividend Comparison 2026

GPOVY yields 0.85% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $8.8K in total portfolio value
10 years
GPOVY
GPOVY
● Live price
0.85%
Share price
$14.14
Annual div
$0.12
5Y div CAGR
65.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$93.5K
Annual income
$37,082.19
Full GPOVY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GPOVY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGPOVYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GPOVY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GPOVY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GPOVY
Annual income on $10K today (after 15% tax)
$72.14/yr
After 10yr DRIP, annual income (after tax)
$31,519.86/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GPOVY beats the other by $10,463.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GPOVY + ABBV for your $10,000?

GPOVY: 50%ABBV: 50%
100% ABBV50/50100% GPOVY
Portfolio after 10yr
$97.9K
Annual income
$30,926.98/yr
Blended yield
31.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GPOVY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.8
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GPOVY buys
0
ABBV buys
0
No recent congressional trades found for GPOVY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGPOVYABBV
Forward yield0.85%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR65.3%40.6%
Portfolio after 10y$93.5K$102.3K
Annual income after 10y$37,082.19$24,771.77
Total dividends collected$68.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: GPOVY vs ABBV ($10,000, DRIP)

YearGPOVY PortfolioGPOVY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,840$140.28$11,550$430.00$710.00ABBV
2$11,834$234.93$13,472$627.96$1.6KABBV
3$13,059$396.20$15,906$926.08$2.8KABBV
4$14,648$675.41$19,071$1,382.55$4.4KABBV
5$16,844$1,170.42$23,302$2,095.81$6.5KABBV
6$20,102$2,079.19$29,150$3,237.93$9.0KABBV
7$25,343$3,833.38$37,536$5,121.41$12.2KABBV
8$34,583$7,465.89$50,079$8,338.38$15.5KABBV
9$52,742$15,738.92$69,753$14,065.80$17.0KABBV
10$93,516$37,082.19$102,337$24,771.77$8.8KABBV

GPOVY vs ABBV: Complete Analysis 2026

GPOVYStock

Grupo Carso, S.A.B. de C.V., together with its subsidiaries, engages in the commercial, industrial, infrastructure and construction, and energy sectors. It operates through Commercial and Consumer, Industrial and Manufacturing, Infrastructure and Construction, and Energy divisions. The company's Commercial and Consumption division operates department stores and boutiques, gift shops, restaurants, coffee shops, electronics, and technology and games stores under the Sears, Sanborns, iShop, Mixup, Claro Shop, and Saks Fifth Avenue brands. The company's Industrial and Manufacturing division provides cables, such as energy, telecommunication, electronic, coaxial, and fiber optics for application in mining, automotive, and other; electric harnesses for automotive industry; precision steel tubing; power transformers; and alternate energy. It serves customers under the Condumex, Latincasa, Vinanel, Condulac, IEM, Precitubo, Sitcom, Microm, Sinergia, Equiter, and Logtec brands. The company's Infrastructure and Construction division constructs roads, tunnels, water treatment plants, and general infrastructure works; oil and geothermic well drilling and drilling services; and oil platforms and equipment for chemical and petroleum industries. It also constructs commercial centers, industrial plants, and office building and houses; and telecommunication facilities, gas pipelines, and aqueducts under the CICSA, Swecomex, Bronco Drilling, Cilsa, GSM, PC Construcciones, and Urvitec brands. The company's Energy division engages in the gas transportation services; and exploration and production of oil, gas, and other hydrocarbons, as well as explores geothermal energy under the Carso Energy, Carso Oil & Gas, and Carso Electric brands. It serves customers in Mexico; Central America, South America, and the Caribbean; the United States; Europe; and internationally. Grupo Carso, S.A.B. de C.V. is incorporated in 1980 and is headquartered in Mexico City, Mexico.

Full GPOVY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GPOVY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GPOVY vs SCHDGPOVY vs JEPIGPOVY vs OGPOVY vs KOGPOVY vs MAINGPOVY vs JNJGPOVY vs MRKGPOVY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.